Table 6.

AE occurring during the treatment phase in >5% of any treatment group (safety population: full and APOE-e4-negative subgroup)

	Number of subjects reporting event
	placebo		2 mg RSG XR		8 mg RSG XR		10 mgdonepezil
	full (n = 165)	APOE ε4 negative (n = 86)	full (n=166)	APOE ε4 negative (n = 85)	full (n = 165)	APOE ε4 negative (n = 86)	full (n = 83)	APOE ε4 negative (n = 42)
Peripheral edema	9 (5)	4 (5)	6 (4)	2 (2)	24 (15)	11 (13)	3 (4)	2 (5)
Diarrhea	1 (<1)	0	2 (1)	1 (1)	4 (2)	3 (3)	4 (5)	1 (2)
Nasopharyngitis	4 (2)	1 (1)	11 (7)	6 (7)	4 (2)	2 (2)	1 (1)	0
Headache	0	0	2 (1)	1 (1)	2 (1)	1 (1)	7 (8)	7 (17)
Hyperlipidemia	1 (<1)	0	9 (5)	3 (4)	1 (<1)	0	2 (2)	0
Nausea	0	0	1 (<1)	0	1 (<1)	1 (1)	4 (5)	3 (7)
Gastroesophageal reflux	1 (<1)	1 (1)	0	0	0	0	2 (2)	2 (5)
Insomnia	1 (<1)	0	0	0	0	0	3 (4)	2 (5)

Values in parentheses denote percentages.